Page 17 - 《中国药房》2025年3期

Docetaxel versus active symptom control for refractory oe‐ vanced，or recurrent gastric cancer （JFMC45-1102）[J].
sophagogastric adenocarcinoma （COUGAR-02）：an open- Int J Cancer，2017，140（1）：188-196.
label，phase 3 randomised controlled trial[J]. Lancet On‐ [45] VAN CUTSEM E，DI BARTOLOMEO M，SMYTH E，
col，2014，15（1）：78-86. et al. Trastuzumab deruxtecan in patients in the USA and
[37] HIRONAKA S，UEDA S，YASUI H，et al. Randomized， Europe with HER2-positive advanced gastric or gastro‐
open-label，phase Ⅲ study comparing irinotecan with pa‐ esophageal junction cancer with disease progression on or
clitaxel in patients with advanced gastric cancer without after a trastuzumab-containing regimen （DESTINY-
severe peritoneal metastasis after failure of prior combina‐ Gastric02）：primary and updated analyses from a single-
tion chemotherapy using fluoropyrimidine plus platinum： arm，phase 2 study[J]. Lancet Oncol，2023，24（7）：
WJOG 4007 trial[J]. J Clin Oncol，2013，31（35）：4438- 744-756.
4444. [46] LI J，DENG Y H，ZHANG W J，et al. Subcutaneous enva‐
[38] HIGUCHI K，TANABE S，SHIMADA K，et al. Biweekly folimab monotherapy in patients with advanced defective
irinotecan plus cisplatin versus irinotecan alone as second- mismatch repair/microsatellite instability high solid tumors
line treatment for advanced gastric cancer：a randomised [J]. J Hematol Oncol，2021，14（1）：95.
phase Ⅲ trial （TCOG GI-0801/BIRIP trial）[J]. Eur J Can‐ [47] LI J，XU Y，ZANG A M，et al. Tislelizumab in previously
cer，2014，50（8）：1437-1445. treated，locally advanced unresectable/metastatic microsa-
[39] FUCHS C S，TOMASEK J，YONG C J，et al. Ramuci‐ tellite instability-high/mismatch repair-deficient solid tu‐
rumab monotherapy for previously treated advanced gas‐ mors[J]. Chung Kuo Yen Cheng Yen Chiu，2024，36（3）：
tric or gastro-oesophageal junction adenocarcinoma 257-269.
（REGARD）：an international，randomised，multicentre， [48] QIN S K，LI J，ZHONG H J，et al. Serplulimab，a novel
placebo-controlled，phase 3 trial[J]. Lancet，2014，383 anti-PD-1 antibody， in patients with microsatellite
（9911）：31-39. instability-high solid tumours：an open-label，single-arm，
[40] WILKE H，MURO K，VAN CUTSEM E，et al. Ramuci‐ multicentre，phase Ⅱ trial[J]. Br J Cancer，2022，127
rumab plus paclitaxel versus placebo plus paclitaxel in pa‐ （12）：2241-2248.
tients with previously treated advanced gastric or gastro- [49] PENG Z，LIU T S，WEI J，et al. Efficacy and safety of a
oesophageal junction adenocarcinoma （RAINBOW）：a novel anti-HER2 therapeutic antibody RC48 in patients
double-blind，randomised phase 3 trial[J]. Lancet Oncol， with HER2-overexpressing，locally advanced or meta‐
2014，15（11）：1224-1235. static gastric or gastroesophageal junction cancer：a single-
[41] XU R H，ZHANG Y Q，PAN H M，et al. Efficacy and arm phase Ⅱ study[J]. Cancer Commun，2021，41（11）：
safety of weekly paclitaxel with or without ramucirumab 1173-1182.
as second-line therapy for the treatment of advanced [50] LI J，QIN S K，XU J M，et al. Randomized，double-blind，
gastric or gastroesophageal junction adenocarcinoma placebo-controlled phase Ⅲ trial of apatinib in patients
（RAINBOW-Asia）：a randomised，multicentre，double- with chemotherapy-refractory advanced or metastatic ad‐
blind，phase 3 trial[J]. Lancet Gastroenterol Hepatol， enocarcinoma of the stomach or gastroesophageal junction
2021，6（12）：1015-1024. [J]. J Clin Oncol，2016，34（13）：1448-1454.
[42] WANG F，SHEN L，GUO W J，et al. Fruquintinib plus pa‐ [51] SHITARA K，BANG Y J，IWASA S，et al. Trastuzumab
clitaxel versus placebo plus paclitaxel for gastric or gastro‐ deruxtecan in previously treated HER2-positive gastric
esophageal junction adenocarcinoma：the randomized cancer[J]. N Engl J Med，2020，382（25）：2419-2430.
phase 3 FRUTIGA trial[J]. Nat Med，2024，30（8）：2189- [52] SHEN L，CHEN P，LU J，et al. 172P trastuzumab deruxte‐
2198. can （T-DXd） in Chinese patients （pts） with previously
[43] WEI X，LI J，YUAN H，et al. 1519P fruquintinib plus sin‐ treated HER2-positive locally advanced/metastatic gastric
tilimab in patients （pts） with either treatment-naïve or pre‐ cancer （GC） or gastroesophageal junction adenocarci‐
viously treated advanced gastric or gastroesophageal junc‐ noma （GEJA）：primary efficacy and safety from the
tion （GEJ） adenocarcinoma：results from a multicenter， phase Ⅱ single-arm DESTINY-Gastric06 （DG06） trial
single-arm phase Ⅱ study[J]. Ann Oncol，2023，34：S856. [J]. Ann Oncol，2023，34：S1542-S1543.
[44] NISHIKAWA K，TAKAHASHI T，TAKAISHI H，et al. [53] XU R H，RUAN D Y，ZHANG D S，et al. A phase 1 trial
Phase Ⅱ study of the effectiveness and safety of trastu‐ of claudin 18.2-specific antibody-drug conjugate
zumab and paclitaxel for taxane- and trastuzumab-naïve CMG901 in patients with advanced gastric/gastroesopha‐
patients with HER2-positive，previously treated，ad‐ geal junction cancer[J]. J Clin Oncol，2023，41（36）：

中国药房 2025年第36卷第3期 China Pharmacy 2025 Vol. 36 No. 3 · 267 ·